Literature DB >> 15521961

Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK.

Simon H S Pearce1.   

Abstract

OBJECTIVE: To determine the frequency and spectrum of serious adverse drug reactions (ADRs) to thionamide antithyroid drugs. DESIGN AND METHODS: Data spontaneously reported to the UK-wide pharmacovigilance agency, The Committee on Safety of Medicines (Yellow Card Scheme), between 1963 and 2003 were analysed to determine the spectrum and relative frequency of ADRs to carbimazole and propylthiouracil. Representative data on the number of dispensed prescriptions were available from 1981, and were used as a denominator to estimate relative reporting rates of ADRs attributed to the drugs.
RESULTS: Between 1981 and 2003 there were 5.23 million prescriptions for thionamide drugs in England and Scotland, 94% of which were for carbimazole. Neutrophil dyscrasia (agranulocytosis and neutropenia) accounted for 49% of all fatalities attributed to these medications. The median time reported for the appearance of neutrophil dyscrasia was 30 days of treatment, but there was a wide range (7-875 days). Neutrophil dyscrasia was more frequently fatal in subjects over 65 years of age; 13.8%vs. 1.2% of fatal reports in younger subjects [odds ratio (OR) 12.90; 5-95% confidence intervals (CI) 1.45-114.92]. Since 1981, reports of most ADRs, including neutrophil dyscrasia, were made significantly more frequently per propylthiouracil prescription dispensed than per carbimazole prescription.
CONCLUSION: Detailed data about ADRs to these compounds, and their patient demography, based on a large number of reports are described. Neutrophil dyscrasia is the commonest life-threatening ADR to thionamides. The excess of ADR reports for propylthiouracil compared to carbimazole could reflect genuine differences in toxicity between the compounds, the relative unfamiliarity of UK physicians with propylthiouracil, or the higher use of propylthiouracil in certain patient groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15521961     DOI: 10.1111/j.1365-2265.2004.02135.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

Review 1.  A strategy for regulatory action when new adverse effects of a licensed product emerge.

Authors:  Jeffrey K Aronson; Deirdre Price; Robin E Ferner
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  Thyroid gland: Antithyroid therapy--best choice of drug and dose.

Authors:  Jayne A Franklyn
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 3.  Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy.

Authors:  Peter N Taylor; Bijay Vaidya
Journal:  Eur Thyroid J       Date:  2012-09-24

4.  Patient knowledge of antithyroid drug-induced agranulocytosis.

Authors:  Jonah Robinson; Max Richardson; Janis Hickey; Andy James; Simon H Pearce; Steve G Ball; Richard Quinton; Margaret Morris; Margaret Miller; Petros Perros
Journal:  Eur Thyroid J       Date:  2014-10-15

5.  Propylthiouracil is teratogenic in murine embryos.

Authors:  Valeria C Benavides; Murali K Mallela; Carmen J Booth; Christopher C Wendler; Scott A Rivkees
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

6.  Fatality complicating agranulocytosis in the setting of carbimazole therapy.

Authors:  Matthew J Lynch; Noel W F Woodford
Journal:  Forensic Sci Med Pathol       Date:  2008-05-14       Impact factor: 2.007

Review 7.  How to use thionamide anti-thyroid drug in the young- what's new?

Authors:  Tim Cheetham
Journal:  Thyroid Res       Date:  2021-07-21

8.  Expert consensus on diagnosis and treatment for elderly with thyroid diseases in China (2021).

Authors:  Youshuo Liu; Zhongyan Shan
Journal:  Aging Med (Milton)       Date:  2021-07-02

9.  Peripheral blood lymphocyte apoptosis and its relationship with thyroid function tests in adolescents with hyperthyroidism due to Graves' disease.

Authors:  Maria Klatka; Ewelina Grywalska; Agata Surdacka; Jerzy Tarach; Janusz Klatka; Jacek Roliński
Journal:  Arch Med Sci       Date:  2012-11-07       Impact factor: 3.318

10.  2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Authors:  George J Kahaly; Luigi Bartalena; Lazlo Hegedüs; Laurence Leenhardt; Kris Poppe; Simon H Pearce
Journal:  Eur Thyroid J       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.